Bio-Rad Laboratories, Inc. Class B
BIO.B Real Time Price USDRecent trades of BIO.B by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in BIO.B holdings by institutional investors
Quarterly net insider trading by BIO.B's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Former government officials who have lobbied for BIO.B
BIO.B Estimated quarterly lobbying spending
BIO.B Revenue by Segment or Geography
New BIO.B patent grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded to BIO.B from public contracts
Recent insights relating to BIO.B
Recent picks made for BIO.B stock on CNBC
ETFs with the largest estimated holdings in BIO.B
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $BIO.B stock a Buy, Sell, or Hold?
- What is the price target for $BIO.B stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $BIO.B stock?
- Who owns the most shares of $BIO.B stock?
- What funds own $BIO.B stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BIO.B Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Bio-Rad Laboratories, Inc. Class B (BIO.B) Historical Stock Prices
Bio-Rad Laboratories, Inc. Class B (BIO.B) closed at $365.08 on August 20, 2026. Over the past year its adjusted close ranged from $255.54 to $365.08. Daily prices go back to January 2, 2014, 610 trading days in all.
- 1 month+18.01%
- 3 months+36.51%
- Year to date+17.50%
- 1 year+47.78%
- 3 years-5.80%
- 5 years-52.14%
- Max+195.76%
Quiver Premium charts BIO.B's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | 365.08 | 365.08 | 365.08 | 365.08 | 365.08 | 103 |
| Aug 3, 2026 | 337.00 | 337.00 | 337.00 | 337.00 | 337.00 | 63 |
| Jul 13, 2026 | 309.37 | 309.37 | 309.37 | 309.37 | 309.37 | 92 |
| Jul 10, 2026 | 298.50 | 298.50 | 298.50 | 298.50 | 298.50 | 57 |
| Jul 8, 2026 | 293.37 | 293.37 | 293.37 | 293.37 | 293.37 | 309 |
| Jun 24, 2026 | 291.99 | 296.49 | 291.99 | 296.49 | 296.49 | 187 |
| Jun 23, 2026 | 297.22 | 297.96 | 289.23 | 290.00 | 290.00 | 818 |
| May 27, 2026 | 304.15 | 304.15 | 304.15 | 304.15 | 304.15 | 59 |
| May 18, 2026 | 267.43 | 267.43 | 267.43 | 267.43 | 267.43 | 102 |
| May 15, 2026 | 253.17 | 260.90 | 253.13 | 260.90 | 260.90 | 595 |
| May 14, 2026 | 244.54 | 260.00 | 244.54 | 260.00 | 260.00 | 3,350 |
| May 8, 2026 | 255.54 | 255.54 | 255.54 | 255.54 | 255.54 | 394 |
| May 6, 2026 | 261.40 | 261.40 | 261.27 | 261.27 | 261.27 | 106 |
| May 5, 2026 | 257.71 | 258.46 | 255.90 | 258.46 | 258.46 | 887 |
| Apr 22, 2026 | 299.45 | 299.45 | 299.45 | 299.45 | 299.45 | 76 |
| Apr 7, 2026 | 277.00 | 277.00 | 277.00 | 277.00 | 277.00 | 103 |
| Mar 31, 2026 | 278.30 | 278.30 | 278.25 | 278.25 | 278.25 | 151 |
| Mar 12, 2026 | 268.55 | 268.55 | 268.55 | 268.55 | 268.55 | 100 |
| Mar 9, 2026 | 267.80 | 268.50 | 267.59 | 268.50 | 268.50 | 286 |
| Mar 4, 2026 | 281.95 | 281.95 | 281.95 | 281.95 | 281.95 | 44 |
| Feb 23, 2026 | 268.88 | 268.88 | 268.88 | 268.88 | 268.88 | 104 |
| Feb 18, 2026 | 261.83 | 261.83 | 261.83 | 261.83 | 261.83 | 50 |
| Feb 13, 2026 | 257.05 | 257.05 | 257.05 | 257.05 | 257.05 | 50 |
| Feb 2, 2026 | 291.36 | 295.05 | 291.36 | 295.05 | 295.05 | 1,915 |
| Jan 20, 2026 | 312.75 | 312.75 | 312.75 | 312.75 | 312.75 | 44 |
| Nov 17, 2025 | 310.45 | 310.70 | 310.45 | 310.70 | 310.70 | 134 |
| Nov 14, 2025 | 315.07 | 315.07 | 314.40 | 314.40 | 314.40 | 89 |
| Nov 6, 2025 | 305.40 | 305.40 | 305.40 | 305.40 | 305.40 | 152 |
| Nov 5, 2025 | 305.79 | 306.10 | 305.55 | 305.85 | 305.85 | 2,093 |
| Oct 30, 2025 | 303.35 | 303.35 | 303.15 | 303.15 | 303.15 | 379 |
| Oct 21, 2025 | 321.12 | 321.12 | 321.12 | 321.12 | 321.12 | 218 |
| Sep 19, 2025 | 283.85 | 284.88 | 283.85 | 284.88 | 284.88 | 357 |
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at BIO.B, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|